Compare ASTRAZENECA PHARMA with Orchid Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs ORCHID PHARMA LTD - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA ORCHID PHARMA LTD ASTRAZENECA PHARMA/
ORCHID PHARMA LTD
 
P/E (TTM) x 105.4 -0.4 - View Chart
P/BV x 30.8 0.1 26,166.7% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ASTRAZENECA PHARMA   ORCHID PHARMA LTD
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
ORCHID PHARMA LTD
Sep-13
ASTRAZENECA PHARMA/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs1,278194 658.8%   
Low Rs88335 2,521.7%   
Sales per share (Unadj.) Rs228.4276.5 82.6%  
Earnings per share (Unadj.) Rs10.4-79.2 -13.1%  
Cash flow per share (Unadj.) Rs16.3-43.5 -37.4%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs98.853.9 183.1%  
Shares outstanding (eoy) m25.0070.45 35.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.70.4 1,142.0%   
Avg P/E ratio x104.2-1.4 -7,210.9%  
P/CF ratio (eoy) x66.4-2.6 -2,521.2%  
Price / Book Value ratio x10.92.1 515.2%  
Dividend payout %00-   
Avg Mkt Cap Rs m27,0088,067 334.8%   
No. of employees `0001.42.8 48.4%   
Total wages/salary Rs m1,5352,527 60.8%   
Avg. sales/employee Rs Th4,210.96,956.1 60.5%   
Avg. wages/employee Rs Th1,132.2902.5 125.5%   
Avg. net profit/employee Rs Th191.1-1,993.0 -9.6%   
INCOME DATA
Net Sales Rs m5,71019,477 29.3%  
Other income Rs m123407 30.1%   
Total revenues Rs m5,83319,884 29.3%   
Gross profit Rs m4631,103 42.0%  
Depreciation Rs m1472,519 5.9%   
Interest Rs m05,227 0.0%   
Profit before tax Rs m438-6,236 -7.0%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m179-125 -142.9%   
Profit after tax Rs m259-5,580 -4.6%  
Gross profit margin %8.15.7 143.2%  
Effective tax rate %40.82.0 2,034.5%   
Net profit margin %4.5-28.7 -15.8%  
BALANCE SHEET DATA
Current assets Rs m3,20911,014 29.1%   
Current liabilities Rs m2,07032,060 6.5%   
Net working cap to sales %20.0-108.1 -18.5%  
Current ratio x1.60.3 451.4%  
Inventory Days Days7295 76.2%  
Debtors Days Days3534 104.1%  
Net fixed assets Rs m79029,440 2.7%   
Share capital Rs m50705 7.1%   
"Free" reserves Rs m2,4192,043 118.4%   
Net worth Rs m2,4693,800 65.0%   
Long term debt Rs m09,018 0.0%   
Total assets Rs m4,60546,510 9.9%  
Interest coverage xNM-0.2-  
Debt to equity ratio x02.4 0.0%  
Sales to assets ratio x1.20.4 296.1%   
Return on assets %5.6-0.8 -740.2%  
Return on equity %10.5-146.9 -7.1%  
Return on capital %17.7-3.7 -475.0%  
Exports to sales %037.9 0.0%   
Imports to sales %022.6 0.0%   
Exports (fob) Rs mNA7,378 0.0%   
Imports (cif) Rs mNA4,406 0.0%   
Fx inflow Rs m3007,513 4.0%   
Fx outflow Rs m2,0155,649 35.7%   
Net fx Rs m-1,7151,865 -92.0%   
CASH FLOW
From Operations Rs m881,682 5.2%  
From Investments Rs m-94-9,860 0.9%  
From Financial Activity Rs mNA6,644 0.0%  
Net Cashflow Rs m-6-1,535 0.4%  

Share Holding

Indian Promoters % 0.0 32.3 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 4.6 6.5%  
FIIs % 15.7 3.3 475.8%  
ADR/GDR % 0.0 4.6 -  
Free float % 9.1 55.3 16.5%  
Shareholders   12,856 84,811 15.2%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   VENUS REMEDIES  SHASUN PHARMA  SANOFI INDIA  TTK HEALTHCARE  PROCTER & GAMBLE HEALTH  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 224 Points Higher; Realty and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended on a positive note.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

6 Charts Showing the State of Indian Financial Markets in 2020(Sector Info)

May 26, 2020

Six charts showing how Indian financial markets have performed in 2020 so far...

This 'Essential Product' Smallcap is a Must Have for a 'Covid-19' Immune Portfolio(Profit Hunter)

May 19, 2020

This smallcap company needs no stimulus measures to do well in the long term.

What the RBI's Rate Cut Means for Options Traders(Fast Profits Daily)

May 25, 2020

The RBI governor has cut the repo rate to 4%. What does this mean for options traders? Find out in this video.

Which Stocks Should You Buy, Sell, and Hold in the Market Today?(Profit Hunter)

May 21, 2020

The coronavirus led uncertainty refuses to go away from the markets. Here's what retail investors should do with their stocks...

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


May 29, 2020 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS